Skip to content
Wenlo
Sign in
← Markets
Market closed · Opens Mon 4:00 AM ET

SMMT Summit Therapeutics Inc.

NASDAQ
$9.96−$0.61 (−5.77%)

As of 3:59 PM ET

  • SMMT

Loading chart…

Open
$10.24
Previous close
$10.57
Day range
9.90 – 10.60
52-week range
9.90 – 29.23
Volume
331.7K
Avg volume (3M)
6.6M
Market cap
$8.4B
P/E (TTM)
25.02
EPS (TTM)
−$1.06
Beta
−1.52
Dividend yield
0.00%
Next earnings
Feb 17, 2027(estimated from past report dates; not yet confirmed by the company)
Ex-dividend
—
Sector
Healthcare

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.

SMMT news and filings

Loading filings…

Filings from SEC EDGAR.